Abbott Laboratories reported Q4 2025 sales of $11.5 billion, representing organic growth of 3.0% (or 3.8% excluding COVID-19 testing), and adjusted EPS of $1.50, up 12%. For the full year 2025, sales reached $44.3 billion with organic growth of 5.5% (6.7% ex-COVID), while adjusted EPS grew 10% to $5.15. The company projects an acceleration in 2026, guiding for 6.5% to 7.5% organic sales growth and adjusted EPS of $5.55 to $5.80.
Key Highlights
- The Medical Devices segment drove results with organic sales growth of 10.4%, led by double-digit growth in Electrophysiology (+12.5%), Heart Failure (+12.1%), and Diabetes Care (+12.2%).
- The Nutrition segment was a notable weak spot, with organic sales declining 9.1% due to lower volumes and strategic price actions aimed at increasing future volume growth.
- Management projects an acceleration for full-year 2026, guiding for organic sales growth of 6.5% to 7.5% and adjusted EPS of $5.55 to $5.80, representing 10% growth at the midpoint.